Charles Genovese
Internal Medicine · Independence, LANPI 1891719985
Payments from drug & device makers
Across 264 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$860
- AbbVie$463
- Renalytix AI, Inc.$338
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
- Supernus Pharmaceuticals, Inc.$261
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,358100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,415 |
| GSK | 63 | $860 |
| AbbVie(2 entities) | 27 | $463 |
| Renalytix AI, Inc. | 23 | $338 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $272 |
| Supernus Pharmaceuticals, Inc. | 17 | $261 |
| Lilly USA, LLC | 9 | $261 |
| Boehringer Ingelheim | 8 | $204 |
| Sunovion Pharmaceuticals Inc. | 14 | $167 |
| Novartis | 5 | $159 |
| Novo Nordisk | 2 | $138 |
| Abbott | 1 | $125 |
| Amgen | 1 | $123 |
| Pfizer | 6 | $122 |
| Indivior Inc. | 6 | $92 |
| Biodelivery Sciences International, Inc. | 6 | $78 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Eisai Inc. | 3 | $54 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| MDD US Operations, LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Gilead | 1 | $17 |
| Bayer | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$626
- FARXIGA$255
- VRAYLAR$126
- CardioMEMS HF System$125
- Ozempic$125
- KRYSTEXXA$123
- TRELEGY ELLIPTA$120
- FASENRA$100
How this compares
$5,358 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 52 | $52,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $34,437 |
| LinzessLinaclotide | 50 | $33,347 |
| FarxigaDapagliflozin Propanediol | 33 | $22,155 |
| EliquisApixaban | 24 | $21,645 |
| OzempicSemaglutide | 22 | $20,731 |
| Restasis MultidoseCyclosporine | 28 | $18,495 |
| XareltoRivaroxaban | 17 | $14,760 |
| JanuviaSitagliptin Phosphate | 22 | $14,304 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,580 |
| MovantikNaloxegol Oxalate | 14 | $7,174 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $4,718 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $3,063 |
| Doxepin Hcl | 44 | $1,940 |
| Gabapentin | 129 | $1,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $204 | $52,96752 claims |
| AbbVieLinzess, Restasis Multidose | $463 | $51,84378 claims |
| GSKTrelegy Ellipta | $860 | $34,43752 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,415 | $32,73550 claims |
| PfizerEliquis | $122 | $21,64524 claims |
| Novo NordiskOzempic | $138 | $20,73122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Independence
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.